Pneumococcal vaccine: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
(Started history)
Line 7: Line 7:


In [[medicine]], pneumococcal vaccines are "[[vaccine]]s or candidate vaccines used to prevent infections with [[streptococcus pneumoniae]]."<ref>{{MeSH}}</ref> These infections include [[pneumonia]], [[meningitis]], [[otitis media]], and [[septic shock|sepsis]].
In [[medicine]], pneumococcal vaccines are "[[vaccine]]s or candidate vaccines used to prevent infections with [[streptococcus pneumoniae]]."<ref>{{MeSH}}</ref> These infections include [[pneumonia]], [[meningitis]], [[otitis media]], and [[septic shock|sepsis]].
==History==
The polyvalent 14 type vaccine was licensed to Merck Sharp & Dohme in 1977.<ref name="urlwww.fda.gov">{{cite web |url=http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131665.pdf |title=Summary for Basis of Approval |author=Bacterial Polysaccharides Branch, DBP |authorlink= |coauthors= |date=June 30, 1983 |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=Merck Sharp & Dohme was licensed for Pneumococcal Vaccine, Polyvalent (14 types) in 1977. |accessdate=2009-08-25}}</ref>The polyvalent 23 type vaccine was licensed to Merck Sharp & Dohme in 1983.<ref name="urlwww.fda.gov">{{cite web |url=http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131665.pdf |title=Summary for Basis of Approval |author=Bacterial Polysaccharides Branch, DBP |authorlink= |coauthors= |date=June 30, 1983 |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=Merck Sharp & Dohme was licensed for Pneumococcal Vaccine, Polyvalent (14 types) in 1977. |accessdate=2009-08-25}}</ref>


==Indications==
==Indications==

Revision as of 23:10, 24 August 2009

This article is a stub and thus not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Pneumococcal_vaccine&printable=yes
This editable Main Article is under development and subject to a disclaimer.
Pneumococcal vaccine
MedlinePlus 007332
MeSH D022242

In medicine, pneumococcal vaccines are "vaccines or candidate vaccines used to prevent infections with streptococcus pneumoniae."[1] These infections include pneumonia, meningitis, otitis media, and sepsis.

History

The polyvalent 14 type vaccine was licensed to Merck Sharp & Dohme in 1977.[2]The polyvalent 23 type vaccine was licensed to Merck Sharp & Dohme in 1983.[2]

Indications

In the United States, the Centers for Disease Control and Prevention[3][4][5] and the Joint Commission on Accreditation of Healthcare Organizations[6] have created recommendations for vaccination. In 2009, the Centers for Disease Control and Prevention added asthma and smoking to the indications for vaccination.[3]

The older clinical practice guidelines by the Infectious Disease Society of America and the American Thoracic Society recommend:

  • Adults >65 years of age
  • Persons >2 years with
    • chronic illness
    • anatomic or functional asplenia
    • immunocompromised (disease, chemotherapy, steroids)
    • Human Immunodeficiency Virus infection
    • environments or settings with increased risk

Efficacy

Ideally, pneumococcal vaccine would protect against pneumonia, invasive pneumococcal disease (bacteremia and meningitis), hospitalizations and death.

Among patients hospitalized for community acquired pneumonia, prior pneumococcal vaccination improved all cause mortality, respiratory failure, and reduced length of stay after adjustment for other factors in a cohort study of over 62,000 patients. [7]


An updated Cochrane review in 2008 found:[8]

  • Randomized controlled trials provided strong evidence of vaccine efficacy against invasive pneumococcal disease (IPD) with no statistical heterogeneity (OR 0.26). Observational studies provided evidence for protection against IPD in populations for whom the vaccine is currently utilized (odds ratio = 0.48).
  • Efficacy against all cause pneumonia was inconclusive with substantial statistical heterogeneity
  • Pneumococcal vaccine was not associated with substantial reductions in all-cause mortality.
  • Vaccine efficacy against primary outcomes appeared poorer in adults with chronic illness but the difference was not statistically significant.

The authors concluded that evidence supports the recommendation for vaccination to prevent IPD in adults, but does not support vaccination to prevent all-cause pneumonia or mortality. [8] A subsequent meta-analysis also concludes that the vaccine does not prevent pneumonia.[9]

There has also been some concern due to the immune response to the traditional pneumococcal vaccine. The conjugated pneumonia vaccine (PCV) is known to have better immunogenicity in children due to this age groups lack of immune response to polysaccharides. A recent trial compared the immunogenicity in elderly patients with recent pneumococcal pneumonia and found that PCV stimulates a more prolonged response than PPV. [10] Musher et. al. concluded that protein vaccines may be needed in the high risk elderly.

Special populations

Two studies suggest that the age for routine vaccination be lowered from 65 to 50 years old.

First, in regards to which people are at risk of invasive pneumococcal disease (IPD), a recent Finnish study found that this diagnosis carried a 12% mortality at one month for patients 65 and over. 46% of those patients that died within 1 month of having IPD did not have an indication for receipt of the vaccination prior to hospitalization, with the age group of 50-64 having proportionally higher mortality. The authors concluded that policy makers should consider lowering the age criteria to 50. [11]

Second, a cost-benefit analysis found vaccination to be cost effective for general populations of adults 50–64 years of age [12] and 65 years of age and older[13].

Vaccination of hospitalized patients

Although vaccination is viewed as purview of primary care physicians, vaccinating inpatients during hospitalizations may improve vaccination rates[14]; however, inpatient vaccination may be difficult to implement[15]. Paradoxically, inpatient strategies may be less successful in hospitals that have a high volume of pneumonia cases.[16]

References

  1. ↑ Anonymous (2024), Pneumococcal vaccine (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ 2.0 2.1 Bacterial Polysaccharides Branch, DBP (June 30, 1983). Summary for Basis of Approval. Retrieved on 2009-08-25. “Merck Sharp & Dohme was licensed for Pneumococcal Vaccine, Polyvalent (14 types) in 1977.”
  3. ↑ 3.0 3.1 Advisory Committee on Immunization Practices (2009-01-06). "Recommended Adult Immunization Schedule: United States, 2009*". Ann Intern Med 150 (1): 40-44. PMID 19124819. Retrieved on 2009-01-06.
  4. ↑ (April 1997) "Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep 46 (RR-8): 1–24. PMID 9132580. [e]
  5. ↑ Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule—United States, October 2007–September 2008. MMWR 2007;56:Q1–Q4.:
  6. ↑ Anonymous (September 19, 2008). Specifications Manual for National Hospital Inpatient Quality Measures (pdf). Joint Commission.
  7. ↑ Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J (April 2006). "Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia". Clin. Infect. Dis. 42 (8): 1093–101. DOI:10.1086/501354. PMID 16575726. Research Blogging.
  8. ↑ 8.0 8.1 Moberley SA, Holden J, Tatham DP, Andrews RM (2008). "Vaccines for preventing pneumococcal infection in adults". Cochrane Database Syst Rev (1): CD000422. DOI:10.1002/14651858.CD000422.pub2. PMID 18253977. Research Blogging.
  9. ↑ Huss A, Scott P, Stuck AE, Trotter C, Egger M (January 2009). "Efficacy of pneumococcal vaccination in adults: a meta-analysis". CMAJ 180 (1): 48–58. DOI:10.1503/cmaj.080734. PMID 19124790. PMC 2612051. Research Blogging.
  10. ↑ Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC (October 2008). "Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia". J. Infect. Dis. 198 (7): 1019–27. DOI:10.1086/591629. PMID 18710324. Research Blogging.
  11. ↑ Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Pekka Nuorti J (2008). "Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies". BMC Infect. Dis. 8: 96. DOI:10.1186/1471-2334-8-96. PMID 18647385. PMC 2507715. Research Blogging.
  12. ↑ Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG (June 2003). "Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race". Ann. Intern. Med. 138 (12): 960–8. PMID 12809452. [e]
  13. ↑ Sisk JE, Moskowitz AJ, Whang W, et al (1997). "Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people". JAMA 278 (16): 1333–9. PMID 9343464. [e]
  14. ↑ Bratzler DW, Houck PM, Jiang H, et al (November 2002). "Failure to vaccinate Medicare inpatients: a missed opportunity". Arch. Intern. Med. 162 (20): 2349–56. PMID 12418949. [e]
  15. ↑ Winston CA, Lindley MC, Wortley PM (2006). "Lessons learned from inpatient vaccination in Michigan". Am J Med Qual 21 (2): 125–33. DOI:10.1177/1062860605284361. PMID 16533904. Research Blogging.
  16. ↑ Lindenauer PK, Behal R, Murray CK, Nsa W, Houck PM, Bratzler DW (February 2006). "Volume, quality of care, and outcome in pneumonia". Ann. Intern. Med. 144 (4): 262–9. PMID 16490912. [e]
Retrieved from "https://citizendium.org/wiki/index.php?title=Pneumococcal_vaccine&oldid=561036"